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Abstract
Patients with diabetes mellitus commonly are suffering 
from atrial fibrillation since these two conditions share 
pathophysiological mechanisms. Catheter ablation of atrial 
fibrillation is the cornerstone therapy for rhythm control in 
symptomatic patients with paroxysmal or persistent atrial 
fibrillation. Data regarding the efficacy and safety of 
catheter ablation from large randomized clinical trials in 
this population are limited. The only available data from 
small clinical trials and meta-analyses have shown a 
superiority of catheter ablation compared to 
antiarrhythmic drugs although there are some limitations.
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Introduction
Atrial fibrillation (AF) is the most common sustained 
arrhythmia in the general population and is related with 
high risk of thromboembolic events and heart failure.  
Epidemiological studies have shown a close relationship 
between diabetes mellitus (DM) and the risk of AF and 
reported that DM is an independent risk factor for AF. 1
The incidence of AF and atrial flutter in patients with DM 
has been reported to be 14.9% and 4%, respectively. 1 The 
inflammation process and the oxidative stress contribute to 
the pathogenesis of apoptosis and to the formation of 
advanced glycosylation end products leading to the so-
called “diabetic cardiomyopathy’’. 2-4 There is evidence 
that the HbA1c level is associated in a linear manner with 
the risk of AF in both diabetic and no diabetic patients. 5
Nevertheless, the strict glycemic control in the ACCORD 
trial has not been correlated with a lower rate of new onset 
AF in diabetic patients although these had an increased risk 
of morbidity and mortality compared to the diabetic 
patients without AF. 6
As catheter ablation (CA) of AF is considered to be a first 
line therapy in selected patients with paroxysmal or non-
paroxysmal AF, it is also employed increasingly in patients 
with DM 7. It should be noted that the increased prevalence 
of coronary artery disease in patients with AF restricts the 
use of the most common antiarrhythmic drugs, such as 
class IA and IC drugs flecainide and propafenone, since 
they could be potentially harmful due to their 
proarrhythmic effect. 8,9 Moreover, it should be taken into 
account that the thromboembolic and bleeding 
complications are definitely more frequent in patients with 
DM who undergo percutaneous interventional procedures, 
such as CA of AF. 10 Despite the large volume of data in 
the literature regarding the CA results in patients with AF, 
data concerning patients with DM are limited to small, 
usually single center non-randomized studies.
Superiority of ablation versus antiarrhythmic drugs 
for the maintenance or sinus rhythm
Nowadays, rhythm control in patients with AF is 
achieved either with antiarrhythmic drugs (AADs) or with 
catheter ablation. Both strategies have been compared in 
clinical trials and ablation has been shown superior to 
AADs. One of the first published randomized trials, were 
designed on this basis, was the A4 study. The reported 
prevalence of DM in the patients underwent CA or 
received AADs was 1.9% and 3.4%, respectively, 
indicating thus that the population of diabetic patients was 
under-represented. This trial demonstrated the superiority 
of CA versus AADs, regarding the maintenance of sinus 
rhythm and quality of life. 11 The largest randomized 
clinical trial which compared the radiofrequency CA with 
AADs, as first line treatment, in patients with paroxysmal 
AF is the MANTRA-PAF study. 12 Although, there was no 
significant difference during the 2-year follow up period in 
the intention to treat analysis between the two groups, the 
recently announced results of the 5-year follow up revealed 
the superiority of the CA on the rhythm control. 12, 13 In this 
trial, enrolled patients with DM were only 4% and 7% of 
the CA and AADs group, respectively. 12 Additionally, in 
the RAAFT-2 trial, which was a similar design clinical 
study, only 1.5% and 6.6% of the patients of the CA and 
AADs group, respectively, suffered from DM. 14
The cornerstone of AF ablation is the circumferential 
electrical isolation of pulmonary veins (PVs) in both in 
patients with paroxysmal and persistent AF, either with 
radiofrequency or with cryoballoon technology. The 
optimal sites of deploying the ablation lesions are the ostia 
of left and right PVs targeting the elimination of PVs 
potentials. The ‘’Achilles heel’’ of the ablation procedures 
is the recurrence of AF and the need for redo-procedures, 
mainly due to electrical reconnection of the PVs or due to 
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the progress of the AF and the structural remodeling of the 
left atrium. 7 Especially in patients with DM, the possibility 
of the presence of atrial fibrosis is higher compared to 
other patients because of the pathogenetic mechanisms that 
have been mentioned before, such as the inflammation 
process. 15,16
Data concerning the efficacy of catheter ablation in 
diabetic patients with atrial fibrillation
A study which enrolled patients with paroxysmal and 
persistent AF who were randomized to undergo CA for AF 
or to receive AADs showed a significant difference after 
12 months follow-up since 42.9% of the patients on the 
AADs group vs. 80% of the CA group were free from AF 
(p=0.001). 9 A meta-analysis of fifteen randomized and/or 
observational studies including 1464 patients with DM 
who underwent CA for symptomatic AF, was recently 
published. The mean follow-up period was 27 months and 
the overall long term efficacy in sinus rhythm after CA was 
66%. After the first CA procedure about 41-56% of the 
patients were free of arrhythmia. About 37% of the patients 
underwent a redo ablation procedure after a mean period 
of 12 months after the first one.  In a meta-regression 
analysis was performed in order to evaluate the potential 
correlation of the baseline characteristics and the incidence 
of the recurrence of AF 17. The higher basal HbA1c levels, 
the advanced age and the higher BMI were correlated with 
a higher AF recurrence rate (p<0.001) suggesting a 
possible pathogenetic mechanism of poor metabolic 
control. It should be noted, that in this meta-analysis, 
neither left atrial enlargement nor paroxysmal versus 
persistent AF were correlated with AF recurrence 5.
Furthermore, data from the German Ablation Registry 
were collected from 51 centers between 2007 and 2010,
comparing the results of CA of AF in patients with DM 
versus those without DM. Totally 4327 patients (333 with 
DM and 3994 without DM) were followed up for a median 
period of 460 days and there were no significant 
differences concerning major adverse cardiac and 
cerebrovascular events (p=0.59%). Patients with DM had 
similar percentages of stroke or transient ischemic attack 
compared to non-diabetic patients (p=0.49). Major or 
moderate bleeding rates were higher in patients with DM 
during the follow-up period (p=0.011). Finally, it should 
be noted that patients with DM reported a significant 
increase in functional New York Heart Association 
(NYHA) class and, on the other hand, patients without DM 
reported a decrease in NYHA class (DM: 50.9% vs. no-
DM: 32.9% NYHA II–IV, p<0.001) 18.
As regarding the antidiabetic drug therapy, pioglitazone 
has been shown to have beneficial effects on CA outcomes. 
A prospective observational study included 150 
consecutive patients with DM who underwent CA and 
were receiving or not pioglitazone. After a single 
procedure and a follow-up period of 15 months, 86.3% of 
the pioglitazone group vs. 70.7% of the control group 
remained in sinus rhythm without AADs (p=0.034). In the 
multivariate analysis, treatment with pioglitazone as well 
as renin-angiotensin inhibitor was associated with reduced 
atrial tachycardias rate. 19
Conclusion
AF is commonly present in diabetic patients and taking 
into account that the prevalence of both is going to increase 
in the near future, more data is required regarding the 
modern therapeutic approaches, like the catheter ablation. 
Structural and electrical remodeling as well as 
inflammation and oxidative processes, seem to play a 
potent role on the initiation and the maintenance of AF in 
diabetic patients. A crucial question is whether catheter 
ablation could be performed in the early stages of the AF, 
especially in diabetic patients, in order to have maximal 
beneficial effects. There are ongoing large scale 
multicenter clinical trials, such as CABANA and EAST 
trials, which are going to add new data in this field. 20,21 In 
the daily clinical practice, the results of the ARREST-AF 
trial, which demonstrated that the aggressive management 
of the risk factors, such as diabetes and body weight, could 
improve the long-term success of AF ablation should be 
taken into account from the physicians. 22
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